文献速递类风湿关节炎

Sarilumab治疗类风湿关节炎的长期安全性:长达7年随访的整合分析

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究整合了8项临床试验及其开放标签扩展期的数据,评估Sarilumab联合csDMARDs或单药治疗类风湿关节炎的长期安全性。结果显示,在最长7.3年的暴露期内,不良事件发生率保持稳定,中性粒细胞减少未增加感染风险。

要点

  • 联合组严重不良事件发生率为9.4/100患者年,严重感染为3.7/100患者年。
  • 单药组严重不良事件发生率为6.7/100患者年,严重感染为1.0/100患者年。
  • 中性粒细胞计数<1000 cells/mm3的发生率联合组13%、单药组15%,未增加感染风险。

核心结论

  • Sarilumab联合csDMARDs或单药治疗的长期安全性特征保持稳定,与IL-6信号抑制类药物的预期特征一致。

研究设计与样本

  • 整合8项临床试验及其开放标签扩展期的数据,联合组2887例患者接受Sarilumab联合csDMARDs,单药组471例患者接受Sarilumab单药治疗。

主要发现

  • 联合组和单药组的中位暴露时间分别为2.8年和1.7年,最大暴露时间分别为7.3年和3.5年,累积不良事件观察期分别为8188和812患者年。
  • 每100患者年的发生率:联合组和单药组严重不良事件分别为9.4和6.7,严重感染分别为3.7和1.0,带状疱疹分别为0.6和0.5(无播散性病例),胃肠道穿孔分别为0.1和0,主要不良心血管事件分别为0.5和0.2,恶性肿瘤分别为0.7和0.6。
  • 联合组和单药组中性粒细胞计数<1000 cells/mm3的发生率分别为13%和15%,中性粒细胞减少与感染或严重感染风险增加无关。
  • 按6个月间隔分析未显示任何不良事件发生率随时间增加的趋势。

临床怎么用

  • 长期使用Sarilumab治疗类风湿关节炎时,需关注严重感染、中性粒细胞减少等不良事件,但中性粒细胞减少不增加感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sarilumab is a human monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor-α. We assessed the long-term safety of sarilumab in patients from eight clinical trials and their open-label extensions. METHODS: Data were pooled from patients with rheumatoid arthritis who received at least one dose of sarilumab in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs; combination group) or as monotherapy (monotherapy group). Treatment-emergent adverse events (AEs) and AEs and laboratory values of special interest were assessed. RESULTS: 2887 patients received sarilumab in combination with csDMARDs and 471 patients received sarilumab monotherapy, with mean exposure of 2.8 years and 1.7 years, maximum exposure 7.3 and 3.5 years, and cumulative AE observation period of 8188 and 812 patient-years, respectively. Incidence rates per 100 patient-years in the combination and monotherapy groups, respectively, were 9.4 and 6.7 for serious AEs, 3.7 and 1.0 for serious infections, 0.6 and 0.5 for herpes zoster (no cases were disseminated), 0.1 and 0 for gastrointestinal perforations, 0.5 and 0.2 for major adverse cardiovascular events, and 0.7 and 0.6 for malignancy. Absolute neutrophil counts <1000 cells/mm3 were recorded in 13% and 15% of patients, respectively. Neutropenia was not associated with increased risk of infection or serious infection. Analysis by 6-month interval showed no signal for increased rate of any AE over time. CONCLUSION: The long-term safety profile of sarilumab, either in combination with csDMARDs or as monotherapy, remained stable and consistent with the anticipated profile of a molecule that inhibits IL6 signalling.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fleischmann R, Genovese MC, Lin Y, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology (Oxford). 2020. PMID: 31312844. doi:10.1093/rheumatology/kez265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。